Ascendis Pharma A/S ADR (ASND)



Ascendis Pharma A/S manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes.

Data as of 2020-10-17
Market Cap8.426 Billion Shares Outstanding53.171 Million Avg 30-day Volume177.062 Thousand
P/E Ratio Dividend Yield EPS-5.46
Price/Sales1150.72 Price cash flow ratio Price free cash flow ratio-40.1
Book Value10.54 Price to Tangible Book15.86 Alpha0.04
Short Interest Ratio % Short Interest to Float R-squared0.065814
BETA0.82409 52-week High/Low166.99 / 92.0 Stddev0.137956
View SEC Filings from ASND instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 12 10 20.0% 10 (0.65%) 9 (0.58%) 11.11%
Funds Holding: 154 149 3.36% 59 (3.85%) 59 (3.77%) 0.0%
13F shares: 48.292 Million 48.022 Million 0.56% 27.413 Million 27.892 Million -1.72%
% Ownership 90.8228 51.5552 58.1245 -11.3%
New Positions: 28 27 3.7% 9 8 12.5%
Increased Positions 66 42 57.14% 23 20 15.0%
Closed Positions 21 21 0.0% 9 13 -30.77%
Reduced Positions 40 60 -33.33% 20 24 -16.67%
Total Calls 381.594 Thousand 453.214 Thousand -15.8% 212.982 Thousand 366.7 Thousand -41.92%
Total Puts 151.7 Thousand 209.256 Thousand -27.51% 2.9 Thousand 77.894 Thousand -96.28%
PUT/CALL Ratio 0.4 0.46 -13.04% 0.01 0.21 -95.24%
1 hedge funds and active managers as identified by through public filings.

Funds Holding ASND (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ASND BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)


Open Market Sells (S)


Exercise Derivative Conversion (M)


Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments